Back to Database
CJC-1295
CJC-1295 (with/without DAC)
Also known as: Modified GRF(1-29), Mod GRF
Low-Moderate
Muscle GrowthFat LossAnti-Aging
A synthetic analog of GHRH that stimulates the pituitary to release growth hormone. Typically combined with Ipamorelin for a 3-5x increase in GH release.
Benefits
Increases growth hormone levels 2-10x
Increases IGF-1 levels 1.5-3x
Promotes muscle growth and protein synthesis
Enhances fat metabolism (lipolysis)
Improves sleep quality and recovery
Anti-aging effects via sustained GH elevation
Side Effects & Risks
Injection site reactionsmild
Water retentionmild
Headachemild
Tingling in extremitiesmoderate
Dosing Information
Typical Dose
100-300 mcg per injection
Administration
Subcutaneous injection
Cycle Length
8-12 weeks on, 4 weeks off
Notes
Best at night before sleep. With DAC: ~8 day half-life. Without DAC: ~30 min.
Legal Status
FDA Status
Not FDA-approved
Availability
Removed from Category 2 Sept 2024; some compounding pharmacies
WADA Status
Banned by WADA (athletes beware)
Evidence
Evidence LevelModerate
Human clinical trial showed dose-dependent GH/IGF-1 increases without serious adverse reactions.
Works Well In These Stacks
Where to Buy
Available from verified suppliers
BiosynTech Research Verified4.5
View Supplier CJC-1295 (no DAC) Economy Vial
LyophilizedPurity: 98%+
COA Available Third-Party TestedIn Stock
PeptideLab Sciences Verified4.8
View Supplier CJC-1295 (no DAC) Research Vial
LyophilizedPurity: 99%+
COA Available Third-Party TestedIn Stock
NovaCompound Rx Verified4.9
View Supplier CJC-1295/Ipamorelin Blend
Pre-MixedPurity: 99%+
COA Available Third-Party Tested Requires PrescriptionIn Stock